Akeso Grants Commercialization Rights for Hypercholesterolemia Drug to Hubei Jumpcan Pharmaceutical Unit
MT Newswires Live
Feb 03
Akeso (HKG:9926) units Akeso Biopharma and AD Pharmaceuticals granted JumpCan Pharmaceutical exclusive commercialization rights for the ebronucimab injection within China, according to a Tuesday Hong Kong bourse filing.
JumpCan Pharmaceutical, a unit of Hubei Jumpcan Pharmaceutical's (SHA:600566), will commercialize and sell the product in China, excluding Hong Kong, the Macao Special Administrative Region, and Taiwan.
Akeso Biopharma and AD Pharmaceuticals will receive a license fee of 80 million yuan under the agreement, along with milestone payments of up to 10 million yuan, from JumpCan Pharmaceutical.
The drug is for the treatment of primary hypercholesterolemia and mixed hyperlipidemia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.